Letter to Editor
BibTex RIS Cite

İkinci doz Pfizer-BioNTech COVID-19 messenger RNA sonrası gelişen Eritema Nodozum olgusu

Year 2022, Volume: 3 Issue: 3, 322 - 323, 30.11.2022
https://doi.org/10.48176/esmj.2022.94

Abstract

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

References

  • 1. Leung AKC, Leong KF, Lam JM. Erythema nodosum.World J Pediatr2018;14: 548–554
  • 2. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg. 2007;26(2):114–25. https://doi.org/10.1016/j. Sder.2007.02.009.
  • 3. De Simone C, Caldarola G, Scaldaferri F, Petito V, Perino F, Arena V, et al. Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. Int J Dermatol. 2016;55(5):e289–94. https://doi.org/10.1111/ ijd.13212
  • 4. Cohen PR. Combined reduced-antigen content tetanus, diphtheria,and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.DermatolTher (Heidelb). 2013;3(2):191-197.
  • 5. Teymour S, Ahram A, Blackwell T, Bhate C, Cohen PJ, Whitworth JM. Erythema nodosum after Moderna mRNA-1273 COVID-19 vaccine. Dermatol Ther. 2022 Jan 4:e15302. doi: 10.1111/dth.15302. Epub ahead of print. PMID: 34984777.
  • 6. Aly MH, Alshehri AA, Mohammed A, Almalki AM, Ahmed WA,Almuflihi AM, et al. First case of erythema nodosum associated with Pfizer vaccine.Cureus. 2021;13(11):e19529. doi:10.7759/cureus.19529
  • 7. Wu X, Lim JHL, Lee JSS, Chio MT. Recurrent erythema nodosumafter the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine.JAAD Int. 2022;6:107-108. doi:10.1016/j.jdin.2021.12.009
  • 8. Dameska, Katerina; Simeonovskı, Viktor. Covid‐19 Vaccine Associated Erythema Nodosum: factors to consider. Dermatologic Therapy, 2022, e15410.

Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report

Year 2022, Volume: 3 Issue: 3, 322 - 323, 30.11.2022
https://doi.org/10.48176/esmj.2022.94

Abstract

Erythema Nodosum (EN) is a panniculitis characterized by acute-onset inflammation of the subcutaneous fat tissue; it can be idiopathic or associated with various clinical conditions such as infections (especially Beta-hemolytic streptococcal infections), medications, pregnancy, inflammatory bowel diseases, Behçet syndrome, sarcoidosis, autoimmune diseases, and malignancies. The pathogenesis is unknown, but a delayed type IV hypersensitivity reaction to certain antigens is hypothesized [1]. EN is characterized clinically by painful tender, nodular, erythematous lesions, typically symmetrically on pretibial surfaces. The occurrence of EN after vaccination is rare and especially post-covid vaccine limited number in the literature. We describe herein, a clinical observation of EN induced by Pfizer-BioNTech COVID-19 messenger RNA vaccine.

References

  • 1. Leung AKC, Leong KF, Lam JM. Erythema nodosum.World J Pediatr2018;14: 548–554
  • 2. Requena L, Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg. 2007;26(2):114–25. https://doi.org/10.1016/j. Sder.2007.02.009.
  • 3. De Simone C, Caldarola G, Scaldaferri F, Petito V, Perino F, Arena V, et al. Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. Int J Dermatol. 2016;55(5):e289–94. https://doi.org/10.1111/ ijd.13212
  • 4. Cohen PR. Combined reduced-antigen content tetanus, diphtheria,and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.DermatolTher (Heidelb). 2013;3(2):191-197.
  • 5. Teymour S, Ahram A, Blackwell T, Bhate C, Cohen PJ, Whitworth JM. Erythema nodosum after Moderna mRNA-1273 COVID-19 vaccine. Dermatol Ther. 2022 Jan 4:e15302. doi: 10.1111/dth.15302. Epub ahead of print. PMID: 34984777.
  • 6. Aly MH, Alshehri AA, Mohammed A, Almalki AM, Ahmed WA,Almuflihi AM, et al. First case of erythema nodosum associated with Pfizer vaccine.Cureus. 2021;13(11):e19529. doi:10.7759/cureus.19529
  • 7. Wu X, Lim JHL, Lee JSS, Chio MT. Recurrent erythema nodosumafter the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine.JAAD Int. 2022;6:107-108. doi:10.1016/j.jdin.2021.12.009
  • 8. Dameska, Katerina; Simeonovskı, Viktor. Covid‐19 Vaccine Associated Erythema Nodosum: factors to consider. Dermatologic Therapy, 2022, e15410.
There are 8 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Letter to the Editor
Authors

Erdal Bodakçi 0000-0002-0402-1525

Publication Date November 30, 2022
Published in Issue Year 2022 Volume: 3 Issue: 3

Cite

APA Bodakçi, E. (2022). Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report. Eskisehir Medical Journal, 3(3), 322-323. https://doi.org/10.48176/esmj.2022.94
AMA Bodakçi E. Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report. Eskisehir Med J. November 2022;3(3):322-323. doi:10.48176/esmj.2022.94
Chicago Bodakçi, Erdal. “Erythema Nodosum After the Second Dose of the Pfizer-BioNTech COVID-19 Messenger RNA Vaccine; A Case Report”. Eskisehir Medical Journal 3, no. 3 (November 2022): 322-23. https://doi.org/10.48176/esmj.2022.94.
EndNote Bodakçi E (November 1, 2022) Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report. Eskisehir Medical Journal 3 3 322–323.
IEEE E. Bodakçi, “Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report”, Eskisehir Med J, vol. 3, no. 3, pp. 322–323, 2022, doi: 10.48176/esmj.2022.94.
ISNAD Bodakçi, Erdal. “Erythema Nodosum After the Second Dose of the Pfizer-BioNTech COVID-19 Messenger RNA Vaccine; A Case Report”. Eskisehir Medical Journal 3/3 (November 2022), 322-323. https://doi.org/10.48176/esmj.2022.94.
JAMA Bodakçi E. Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report. Eskisehir Med J. 2022;3:322–323.
MLA Bodakçi, Erdal. “Erythema Nodosum After the Second Dose of the Pfizer-BioNTech COVID-19 Messenger RNA Vaccine; A Case Report”. Eskisehir Medical Journal, vol. 3, no. 3, 2022, pp. 322-3, doi:10.48176/esmj.2022.94.
Vancouver Bodakçi E. Erythema Nodosum after the second dose of the Pfizer-BioNTech COVID-19 messenger RNA vaccine; a case report. Eskisehir Med J. 2022;3(3):322-3.